An incubation period is the span after a strategy is finished but before capital is allocated, when the strategy runs on live market data and records what it would have done in real time.

An incubation period is the span after a strategy is finished but before capital is allocated, when the strategy runs on live market data and records what it would have done in real time. In the framing supported by Sonar Sciences’ research workflow, this stage sits between research completion and publishing, and it exists to create evidence that was not available during development and therefore could not have been tuned to fit the strategy design process [1].

That distinction matters because backtests are vulnerable to overfitting. Sonar’s backtest overfitting audit describes the core problem: repeated testing, parameter selection, and model choice can produce results that look strong in sample even when they arise from noise rather than durable structure [2]. If a researcher keeps iterating on a strategy using the same historical record, then the final backtest may reflect some degree of adaptation to that record. Once that happens, the backtest alone cannot be the first unbiased evidence.

An incubation period addresses that by shifting evaluation onto a data stream that arrives after the strategy has been finalized. Because those observations were not available during tuning, they provide the first opportunity to compare realized live-data behavior with the expectations implied by the backtest without contaminating the evidence with further optimization [1][2]. In that sense, the incubation period does not prove a strategy is valid in any absolute way, but it does create the first evidence that is outside the tuning loop.

Statistical significance measures tied to backtest‑overfitting assessment, including the deflated Sharpe ratio, can be used during incubation [2][3].

The deflated Sharpe ratio is relevant here because it is designed to assess whether an observed Sharpe ratio is statistically distinguishable from what might be expected by chance after accounting for selection effects and non‑normality concerns discussed in Sonar’s glossary entry [3]. In practical research terms, that makes it more appropriate than a raw Sharpe ratio when a strategy has emerged from a process involving many trials or variants. If a researcher compares pre‑existing backtest expectations with incubation‑period observations, then a deflated Sharpe ratio can help frame whether the apparent quality of the strategy survives a more skeptical statistical test [2][3].

So the strongest source‑supported version of the claim is this: an incubation period in which a completed strategy runs on live market data without capital allocation creates the first out‑of‑development evidence, and therefore the first evidence that could not have been directly tuned during research [1]. That evidence is especially important in the presence of overfitting risk identified in Sonar’s audit materials [2]. Statistical tools such as the deflated Sharpe ratio can then be used to judge whether observed risk‑adjusted performance is more likely to reflect genuine signal than multiple‑testing luck [3].

Incubation produces the first live, untuned evidence against the hypothesis that the strategy’s apparent quality is entirely an artifact of historical fitting, and that evidence becomes more informative when evaluated with overfitting‑aware statistics such as the deflated Sharpe ratio [1][2][3].

Covered in depth in the From research to publishing pillar hub.